Interobserver and Intraobserver Variability of Standardized Uptake Value Measurements in Non–small-cell Lung Cancer
- 1 August 2006
- journal article
- research article
- Published by Ovid Technologies (Wolters Kluwer Health) in Journal of Thoracic Imaging
- Vol. 21 (3), 205-212
- https://doi.org/10.1097/01.rti.0000213643.49664.4d
Abstract
To assess interobserver and intraobserver variabilities in measuring the maximal standardized uptake value (SUV) of non-small-cell lung cancer. Positron emission tomography-computed tomography examinations of 20 consecutive patients referred for initial evaluation of newly diagnosed non-small-cell lung cancer were retrospectively reviewed by 5 experienced positron emission tomography-computed tomography readers, who independently measured the maximal SUV/body weight of the primary tumors. Interobserver and intraobserver variabilities were assessed by using 4 statistical methods: correlation, regression analysis, Bland-Altman analysis, and analysis of variance. The SUV measurements derived in the study were compared with the SUV measurements documented in the original reports using correlation and regression analysis. The percentages of tumors whose retrospective SUV measurements were more than 20% different and more than 25% different from those in the original report were assessed. Both interobserver and intraobserver SUV measurements were highly reproducible. Pearson correlation coefficients were greater than 0.95 and 0.94, respectively. Good interobserver and intraobserver agreement was shown with regression analysis (F test P value >0.05), the Bland-Altman analysis, and analysis of variance (F test P value >0.95). The mean original SUV was much less than the mean study SUV (P<0.05). The study SUV differed from the SUV of the original report by more than 20% in 50% of the tumors, and by more than 25% in 45% of the tumors. There was excellent interobserver and intraobserver agreement in SUVs measured in the study environment but poor agreement between study SUVs and those documented in original reports, which can affect treatment decisions substantially.Keywords
This publication has 33 references indexed in Scilit:
- Value of F-18-fluorodeoxyglucose positron emission tomography after induction therapy of locally advanced bronchogenic carcinomaThe Journal of Thoracic and Cardiovascular Surgery, 2004
- Value of F-18-fluorodeoxyglucose positron emission tomography after induction therapy of locally advanced bronchogenic carcinomaThe Journal of Thoracic and Cardiovascular Surgery, 2004
- Pre-transplant positron emission tomography (PET) using fluorine-18-fluoro-deoxyglucose (FDG) predicts outcome in patients treated with high-dose chemotherapy and autologous stem cell transplantation for non-Hodgkin's lymphomaBone Marrow Transplantation, 2002
- Imaging in lung cancer: positron emission tomography scanEuropean Respiratory Journal, 2002
- Anatomy of SUVNuclear Medicine and Biology, 2000
- Measurement of clinical and subclinical tumour response using [18F]-fluorodeoxyglucose and positron emission tomography: review and 1999 EORTC recommendationsEuropean Journal Of Cancer, 1999
- Present status of induction treatment in stage IIIA-N2 non-small cell lung cancer: a reviewEuropean Journal of Cardio-Thoracic Surgery, 1998
- Assessment of Axillary Lymph Node Involvement in Breast Cancer Patients With Positron Emission Tomography Using Radiolabeled 2-(Fluorine-18)-fluoro-2-deoxy-D-glucoseJNCI Journal of the National Cancer Institute, 1996
- Combined modality therapy for stage IIIA non-small cell carcinoma of the lungEuropean Journal Of Cancer, 1993
- Randomized trial of neoadjuvant therapy for lung cancer: Interim analysisThe Annals of Thoracic Surgery, 1992